Last Updated: May 26, 2026Reviewed by: Andrei Dokukin, MDTier B — Clinical evidence (off-label)GRADE: Moderate

Off-label, multiple RCTsPending dedicated FDA indication

Clinical Evidence — Not FDA-Evaluated

Musculoskeletal applications have Tier B (amber) evidence — published randomized controlled trials demonstrate clinical benefit for knee osteoarthritis, lateral epicondylitis, and thumb carpometacarpal osteoarthritis. This is the strongest evidence base for hirudotherapy outside the FDA 510(k)-cleared microsurgical indication. These musculoskeletal applications are not included in the FDA 510(k) clearance for medicinal leeches.

Investigational Application

Musculoskeletal conditions (osteoarthritis, epicondylitis, joint disease) is not included in the FDA 510(k) clearance for medicinal leeches. The information below summarizes international clinical experience and published research. ASH advocates for rigorous clinical evaluation of these applications.

International Clinical Evidence

The following evidence reflects international clinical experience. Practice standards, regulatory frameworks, and levels of evidence vary by jurisdiction. U.S. practitioners should refer to FDA guidance and applicable state regulations.

Musculoskeletal conditions — particularly knee osteoarthritis — represent the strongest evidence area for hirudotherapy outside the FDA-cleared surgical indication. Five randomized controlled trials from German academic medical centers provide controlled clinical data with validated outcome measures (WOMAC, VAS, DASH, SF-36), including the landmark Michalsen 2003 trial published in the Annals of Internal Medicine. A 2014 Cochrane-style systematic review and meta-analysis confirmed significant pooled effect sizes for pain and function. The biological rationale rests on the multi-targeted anti-inflammatory and analgesic profile of leech salivary gland secretion (SGS), which contains at least seven distinct compounds acting on inflammatory pathways relevant to joint disease.

Knee Osteoarthritis — Randomized Controlled Trial Evidence

GRADE Evidence Level: Moderate

RCTs with limitations or strong observational studies

Knee osteoarthritis (OA) is the most extensively studied musculoskeletal indication for hirudotherapy. The evidence base includes two independent RCTs (Michalsen 2003 with 91-day follow-up; Andereya 2008 with 26-week follow-up; the Andereya trial was sham-controlled, with a simulated 'artificial leech'), and one systematic review with meta-analysis (Lauche 2014). Collectively, these studies enrolled 164 patients (51 + 113) at two German academic medical centers (Essen and Aachen) and demonstrate consistent, clinically significant improvements in pain, function, and stiffness.

Landmark Trial: Michalsen et al. 2003

The Michalsen 2003 RCT, published in the Annals of Internal Medicine, is the single most important study in musculoskeletal hirudotherapy. A single session of 4–6 leeches applied to the affected knee produced approximately 60% pain reduction at day 7, compared to approximately 18% with topical diclofenac — the standard first-line topical NSAID. The pain difference was no longer significant after day 7, but differences in function, stiffness and total symptoms remained significant in favor of leech therapy until the end of the study (day 91). This trial established the evidence foundation for all subsequent musculoskeletal research.

Knee Osteoarthritis — Randomized Controlled Trials and Systematic Review
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Michalsen et al. 2003	Randomized controlled trial	Patients with symptomatic knee osteoarthritis (Kellgren-Lawrence grade II-III) (n=NR)	Single application of 4-6 leeches to the affected knee vs topical diclofenac gel (applied at least twice daily for 28 days)	Primary: WOMAC pain subscale at day 7. Secondary: WOMAC function, stiffness, VAS pain, SF-36 at days 7 and 28	Leech therapy significantly superior: WOMAC pain fell from 53.5 to 19.3 with leeches vs 51.5 to 42.4 with diclofenac at day 7 (P < 0.001); the pain difference was no longer significant at days 28 and 91. Significant improvement in WOMAC function and stiffness subscales Published in Annals of Internal Medicine. University of Duisburg-Essen, Germany. Randomized controlled trial, n=51, versus topical diclofenac. Single session produced sustained 28-day benefit
Andereya et al. 2008	Randomized controlled trial	Patients with symptomatic knee osteoarthritis, bilateral or unilateral (n=NR)	Single application of 4 leeches (n=38), two applications 4 weeks apart (n=35), or simulated treatment with an "artificial leech" (n=40); follow-up 26 weeks	WOMAC composite score, VAS pain, SF-36 at multiple timepoints through 91-day follow-up	Both leech groups (single and double application) showed significant improvement in KOOS, WOMAC and VAS pain throughout the 26-week follow-up, with reduced analgesic requirement; scores also improved in the artificial-leech control group, but without statistical significance. Follow-up was longer than in Michalsen 2003 (91 days) University of Aachen, Germany. Largest knee OA RCT (n=113). Patient-blinded, with a simulated 'artificial leech' control and 26-week follow-up; it did not compare leeches with diclofenac
Lauche et al. 2014	Systematic review and meta-analysis	All published RCTs of leech therapy for osteoarthritis (n=NR)	Leech therapy vs active comparators (topical diclofenac, TENS) across pooled RCTs	Pooled effect sizes for pain, function, and stiffness outcomes	Meta-analysis demonstrated significant pooled effect sizes favoring leech therapy for pain (immediate effect SMD -1.05, P<0.01; 3 RCTs and 1 non-randomized controlled trial, 237 patients) and function (immediate SMD -0.72, P<0.01). The authors rated the evidence as moderate to strong Systematic review and meta-analysis of 3 RCTs and 1 non-randomized controlled trial (237 patients with knee osteoarthritis). Published in Clinical Journal of Pain. Provided the first pooled quantitative estimate of leech therapy efficacy for OA
Andereya et al. 2006		Patients with symptomatic knee osteoarthritis (n=NR)			The sham-controlled design addressed a key limitation of the Michalsen 2003 trial, which used an active comparator (diclofenac) rather than sham. University of Aachen

Key Findings Across Knee OA Trials

The convergence of evidence from multiple independent research groups is notable. Three observations are consistent across all knee OA studies:

Magnitude of effect: Pain reduction with a single leech therapy session exceeded that of topical diclofenac in Michalsen 2003 (the only knee OA trial with that comparator; the others used a sham control or TENS) for knee OA. The Lauche 2014 meta-analysis calculated a standardized mean difference of −1.05 for immediate pain reduction — a large effect size by conventional criteria.
Durability of effect: A single treatment session was followed by improvement lasting up to 91 days (Michalsen 2003) and, with repeated sessions, up to 6 months (Isik 2017: three weekly sessions, day 180). Andereya 2008 reported that improvement in the leech groups remained statistically significant during the complete follow-up period (analgesic use was monitored over 26 weeks), far exceeding the pharmacokinetic half-life of any individual SGS component. This suggests that the therapeutic mechanism involves biological processes beyond direct pharmacologic action.
Multi-domain improvement: Benefits are not limited to pain. WOMAC function and stiffness subscales, and quality-of-life measures (SF-36) all demonstrate significant improvement, indicating that leech therapy addresses the overall disease burden rather than isolated symptom relief.

Addressing the Placebo Question

A common criticism of leech therapy trials is the difficulty of blinding — patients know whether leeches are applied. The Andereya 2008 trial addressed this concern with a sham control: treatment in the control group was simulated with an 'artificial leech'. KOOS, WOMAC and VAS scores improved in all three groups, and the improvements were statistically significant in the leech-treated groups; the authors state that they could not determine whether the benefit was caused by active substances released during leeching, the placebo effect, or the high expectations placed on this unusual treatment form.

Comparison with Other OA Interventions

For context, in the Michalsen 2003 randomized trial a single leech session reduced WOMAC pain from 53.5 to 19.3 at day 7 (about 64%), versus 51.5 to 42.4 with topical diclofenac; the group difference in pain was no longer significant after day 7, whereas differences in function, stiffness and total symptoms remained significant through day 91.

Regulatory Context

While the RCT evidence for knee OA is among the strongest in complementary medicine, hirudotherapy is not FDA-cleared for osteoarthritis or any musculoskeletal indication. The FDA 510(k) clearance for medicinal leeches is limited to venous congestion relief in microsurgical procedures. The studies reviewed here represent investigational applications supported by peer-reviewed clinical research.

Mechanism of Action in Joint Disease

The therapeutic effect of hirudotherapy in musculoskeletal conditions is mediated by the salivary gland secretion (SGS) of Hirudo medicinalis, which contains at least seven distinct anti-inflammatory components operating through independent biochemical pathways. This multi-targeted profile is particularly relevant to joint disease, where inflammation involves neutrophil proteinases, complement activation, mast cell degranulation, and bradykinin-mediated pain signaling simultaneously.

Eglins — Neutrophil Proteinase Inhibitors

Eglins inhibit neutrophil elastase, cathepsin G, and chymotrypsin — granulocyte proteinases released during the neutrophil oxidative burst. In osteoarthritis, neutrophil elastase contributes directly to cartilage matrix degradation by cleaving type II collagen and aggrecan. By blocking this enzymatic cascade, eglins may reduce inflammation-driven cartilage damage at the molecular level.

Other Musculoskeletal Applications — Observational Evidence
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Uncontrolled report (unverifiable) 1997	Prospective cohort	Patients with joint disorders and post-amputation stumps (n=NR)	Hirudotherapy for post-amputation stumps and for hemostatic parameters in joint disorders has been described only in Russian-language reports (Sulim 1997, 1998, as cited by Baskova & Isakhanyan 2004) that are not independently verifiable.	Coagulation parameters, blood rheology, clinical improvement	Claims of pre-treatment coagulation-time shortening in patients with joint disorders and of restored blood rheology in post-amputation stumps derive from Russian-language reports (Sulim 1997, 1998, cited in Baskova & Isakhanyan 2004) that are not independently verifiable. Reported in Russian-language sources cited by Baskova & Isakhanyan 2004; not independently verified and does not establish a hemostatic effect
Starodubskaya 1998	Short report (design not stated)	Patients with inflammatory joint diseases (n=NR)	Hirudotherapy for joint inflammation	Anti-inflammatory clinical response	Analgesic and anti-inflammatory effects reported with leeches applied to the affected joint Evidence level IV. Russian-language literature.
Uncontrolled Russian-language reports (not independently verifiable) 1999	Case series	Patients with inflammatory joint diseases (n=NR)	Hirudotherapy as adjunctive anti-inflammatory treatment for joint disease	Anti-inflammatory response and clinical improvement	Demonstrated anti-inflammatory effects in joint diseases, supporting the biological rationale from SGS composition Evidence level IV. Russian-language literature. Complements the Starodubskaya 1998 findings

Inflammatory Arthritis

Uncontrolled Russian-language reports have described anti-inflammatory effects in inflammatory joint diseases, but these are not independently verifiable. The multi-targeted anti-inflammatory profile of SGS (complement inhibition, proteinase inhibition, mast cell protease inhibition) provides a biological rationale for application in inflammatory arthritis. However, no controlled trials have been conducted, and the interaction between hirudotherapy and disease-modifying antirheumatic drugs (DMARDs) has not been studied. Evidence level: IV.

Treatment	Pain Reduction	Duration	Limitations
Intra-articular corticosteroids	50–70%	4–8 weeks	Cartilage degradation concern with repeated injections
Hyaluronic acid injections	30–40%	3–6 months	Variable efficacy; cost; requires multiple injections
Leech therapy (Michalsen 2003)	~60%	28–91 days	Not FDA-cleared for OA; limited RCT sample sizes
Physical therapy / exercise	20–40%	Sustained with continued exercise	Requires ongoing compliance; slow onset

Comparison Context

The treatment comparison above is derived from published literature and is provided for educational context only. It does not constitute a treatment recommendation. Direct head-to-head comparisons between leech therapy and intra-articular injections, physical therapy, or oral NSAIDs have not been conducted. Treatment decisions should be individualized by the treating clinician.

Practical Application Considerations

The musculoskeletal RCTs provide consistent protocols that inform clinical practice. While specific treatment protocols should be determined by trained practitioners, the following observations from published trials characterize the procedural parameters studied:

Knee Osteoarthritis Protocol (from RCTs)

• Number of leeches: 4–6 per session
• Application sites: Medial and lateral joint line, periarticular soft tissue at points of maximum tenderness
• Sessions: Single session in Michalsen 2003; Andereya 2008 compared a single session with a repeat session 4 weeks later
• Feeding time: Typically 30–90 minutes until spontaneous detachment
• Post-detachment care: Sterile dressing; allow bleeding for 4–24 hours
• Documented effect duration: up to 91 days (Michalsen 2003) and 26 weeks (Andereya 2008) from a single session

1. Larger Multicenter RCTs for Knee OA

The existing RCTs are well-designed but small (n=51–113). A multicenter trial with 200–300 patients, stratified by OA severity (Kellgren-Lawrence grade), would provide definitive evidence and enable subgroup analyses. The WOMAC endpoint used in most existing knee trials (Stange 2012 used the Lequesne index) facilitates study design and power calculations.

2. Long-Term Follow-Up (>6 Months)

The longest published follow-up we identified is about 6 months (Isik 2017, day 180; Andereya 2008 monitored analgesic use over 26 weeks). Extending follow-up to 12 months and beyond would determine whether the observed effects are truly sustained or whether repeated sessions are needed. Long-term safety data would also strengthen the evidence for chronic musculoskeletal conditions.

3. Dose-Response Relationship

Most published RCTs used a single treatment session; Andereya 2008 added a double-application group (second treatment after 4 weeks) and Isik 2017 applied five leeches once weekly for 3 weeks. Whether multiple sessions provide additive benefit, and what the optimal interval between sessions might be, remain unknown. A dose-finding study comparing single vs. repeated sessions (e.g., weekly for 3 weeks) would address this critical clinical question.

4. Head-to-Head Comparisons

No trials have compared leech therapy directly to intra-articular corticosteroid or hyaluronic acid injections. A non-inferiority trial against corticosteroid injection — with the added advantage of avoiding steroid-related cartilage concerns — would be informative.

5. Tendinopathy Expansion

The Bäcker 2011 epicondylitis RCT provides proof of concept for tendinopathy. RCTs for Achilles tendinopathy, rotator cuff tendinopathy, and patellar tendinopathy are warranted. These are common conditions with limited conservative treatment options and established validated outcome measures (VISA-A, DASH, KOOS).

6. Cost-Effectiveness Analysis

A single leech therapy session uses 2–8 leeches (2–3 for thumb-base osteoarthritis, 2–4 for epicondylitis, 4–6 for knee osteoarthritis, 8 in Stange 2012) at about $18–20 each in the US (Leeches USA list price: $20.15 each for 7-99 leeches, $18.15 each for 100 or more; roughly $36–160 direct leech cost). Compared to the cumulative cost of months of topical NSAIDs, repeated corticosteroid injections, or surgical intervention, leech therapy may be highly cost-effective. A formal cost-effectiveness analysis using QALY methodology is needed.

The Path Forward

Knee osteoarthritis represents the most promising indication for a definitive trial. The existing evidence base (4 RCTs, 2 meta-analyses), standardized endpoint (WOMAC), and large patient population create optimal conditions for a definitive multicenter trial. ASH supports the development of such a trial in collaboration with academic medical centers and musculoskeletal research networks.

Key Takeaways

Strongest Non-Surgical Evidence

Musculoskeletal conditions have the strongest hirudotherapy evidence base outside the FDA-cleared microsurgical indication. Seven randomized trials (four in knee osteoarthritis, one each in thumb-base osteoarthritis, lateral epicondylitis and chronic low back pain; one of them sham-controlled) and two systematic reviews with meta-analysis (Lauche 2014, Wang 2018) provide Tier B evidence.

Key References

Andereya S, Stanzel S, Maus U, et al. Assessment of leech therapy for knee osteoarthritis: a randomized study. Acta Orthop. 2008;79(2):235-243.

Lauche R, Cramer H, Langhorst J, Dobos G. A systematic review and meta-analysis of medical leech therapy for osteoarthritis of the knee. Clin J Pain. 2014;30(1):63-72.

Bäcker M, Lüdtke R, Afra D, et al. Effectiveness of leech therapy in chronic lateral epicondylitis: a randomized controlled trial. Clin J Pain. 2011;27(5):442-447. doi:10.1097/AJP.0b013e318208c95b

Stange R, Moser C, Hopfenmueller W, Mansmann U, Buehring M, Uehleke B. Randomised controlled trial with medical leeches for osteoarthritis of the knee. Complement Ther Med. 2012;20(1-2):1-7.

Hohmann CD, Stange R, Steckhan N, et al. The effectiveness of leech therapy in chronic low back pain. Dtsch Arztebl Int. 2018;115(47):785-792.

Starodubskaya EA. Hirudotherapy in a sanatorium-preventorium setting. In: Treatment with Medicinal Leeches and Their Preparations, Collection of Articles, Association of Hirudologists 1992-1997, Vol. II. Moscow. 1998:39-40.

Melnik LS, Razumova AV. Experience with combined apitherapy and hirudotherapy at the Sanatoria-Preventorium "Salampi" of the Chuvashenergo Joint Stock Company. In: Clinical and Experimental Hirudology at the Threshold of the New Millennium, Proceedings of the 6th Scientific-Practical Conference of the Association of Hirudologists of Russia and CIS Countries. Pyatigorsk. 1999:83-84.

Sulim NI. Hirudotherapy in patients with joint disorders. 1997-1998. n=162.

Gileva OS. Anti-exudative action and stimulation of nonspecific resistance by hirudotherapy. 1997.

Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev. 2010;62(4):726-759.

Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785-797.

Caughey GH. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev. 2007;217:141-154.

Musculoskeletal Evidence